Effects of switching from Depakene to generic valproic acid on individuals with mental retardation

V. J. Vadney; K. W. Kraushaar; D. L. Coulter; T. A. Kastner

doi:10.1352/0047-6765(1997)035<0468:eosfdt>2.0.co;2

Effects of switching from Depakene to generic valproic acid on individuals with mental retardation

V. J. Vadney, K. W. Kraushaar, D. L. Coulter, T. A. Kastner

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

In an 8-week open-trial substitution study, 64 subjects with seizure disorders living at an ICF/MR were randomly assigned to either brand-named Depakene or generic Valproic Acid USP (Solvay) medication. After 4 weeks, they were switched to the other medication. Blood levels and seizures were monitored. The price of the generic Valproic Acid was less than one tenth the price of Depakene. Results show that subjects had no statistically significant changes in seizures or blood levels when the two treatment regimens were compared. These findings suggest that generic Valproic Acid USP (Solvay) may be successfully used in this population, resulting in substantial cost savings.

Original language	English (US)
Pages (from-to)	468-476
Number of pages	9
Journal	Mental retardation
Volume	35
Issue number	6
DOIs	https://doi.org/10.1352/0047-6765(1997)035<0468:eosfdt>2.0.co;2
State	Published - 1997
Externally published	Yes

ASJC Scopus subject areas

Education
Rehabilitation
General Health Professions

Access to Document

10.1352/0047-6765(1997)035<0468:eosfdt>2.0.co;2

Cite this

@article{addfba20a65d44a488b3ca6b1fd5dd17,

title = "Effects of switching from Depakene to generic valproic acid on individuals with mental retardation",

abstract = "In an 8-week open-trial substitution study, 64 subjects with seizure disorders living at an ICF/MR were randomly assigned to either brand-named Depakene or generic Valproic Acid USP (Solvay) medication. After 4 weeks, they were switched to the other medication. Blood levels and seizures were monitored. The price of the generic Valproic Acid was less than one tenth the price of Depakene. Results show that subjects had no statistically significant changes in seizures or blood levels when the two treatment regimens were compared. These findings suggest that generic Valproic Acid USP (Solvay) may be successfully used in this population, resulting in substantial cost savings.",

author = "Vadney, {V. J.} and Kraushaar, {K. W.} and Coulter, {D. L.} and Kastner, {T. A.}",

year = "1997",

doi = "10.1352/0047-6765(1997)035<0468:eosfdt>2.0.co;2",

language = "English (US)",

volume = "35",

pages = "468--476",

journal = "Mental retardation",

issn = "0047-6765",

publisher = "American Association on Intellectual and Developmental Disabilities",

number = "6",

}

TY - JOUR

T1 - Effects of switching from Depakene to generic valproic acid on individuals with mental retardation

AU - Vadney, V. J.

AU - Kraushaar, K. W.

AU - Coulter, D. L.

AU - Kastner, T. A.

PY - 1997

Y1 - 1997

N2 - In an 8-week open-trial substitution study, 64 subjects with seizure disorders living at an ICF/MR were randomly assigned to either brand-named Depakene or generic Valproic Acid USP (Solvay) medication. After 4 weeks, they were switched to the other medication. Blood levels and seizures were monitored. The price of the generic Valproic Acid was less than one tenth the price of Depakene. Results show that subjects had no statistically significant changes in seizures or blood levels when the two treatment regimens were compared. These findings suggest that generic Valproic Acid USP (Solvay) may be successfully used in this population, resulting in substantial cost savings.

AB - In an 8-week open-trial substitution study, 64 subjects with seizure disorders living at an ICF/MR were randomly assigned to either brand-named Depakene or generic Valproic Acid USP (Solvay) medication. After 4 weeks, they were switched to the other medication. Blood levels and seizures were monitored. The price of the generic Valproic Acid was less than one tenth the price of Depakene. Results show that subjects had no statistically significant changes in seizures or blood levels when the two treatment regimens were compared. These findings suggest that generic Valproic Acid USP (Solvay) may be successfully used in this population, resulting in substantial cost savings.

UR - http://www.scopus.com/inward/record.url?scp=0031466807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031466807&partnerID=8YFLogxK

U2 - 10.1352/0047-6765(1997)035<0468:eosfdt>2.0.co;2

DO - 10.1352/0047-6765(1997)035<0468:eosfdt>2.0.co;2

M3 - Article

C2 - 9425876

AN - SCOPUS:0031466807

SN - 0047-6765

VL - 35

SP - 468

EP - 476

JO - Mental retardation

JF - Mental retardation

IS - 6

ER -

Effects of switching from Depakene to generic valproic acid on individuals with mental retardation

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this